VNDA Vanda Pharmaceuticals Inc.

+0.28  (+2%)
Previous Close 14.91
Open 15.06
Price To Book 2.73
Market Cap 809,230,359
Shares 53,273,888
Volume 724,320
Short Ratio
Av. Daily Volume 818,487

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial initiated 2Q 2019.
PK trial initiated with full enrollment completed 4Q 2017.
HETLIOZ (tasimelteon) - pediatric formulation
Approved May 26, 2016.
Supplemental New Drug Application (sNDA) as a maintenance treatment of schizophrenia in adults.
Approved January 31, 2014.
HETLIOZ (tasimelteon)
PDUFA date August 16, 2019. However, noted July 22, 2019 that the FDA has identified deficiencies that preclude discussion of labeling.
HETLIOZ (tasimelteon)
Jet Lag Disorder
sNDA filing due 3Q 2019.
HETLIOZ (tasimelteon)
Smith-Magenis Syndrome
Phase 3 data due 1H 2020.
Atopic dermatitis
Phase 1 initiated October 2018.
Hematologic malignancies
Phase 3 trial to be initiated 3Q 2019.
Motion sickness
Randomized trial to commence in 2019.
Bipolar Disorder
Phase 2 trial to be initiated 3Q 2019.
HETLIOZ (tasimelteon)
Delayed sleep phase disorder (DSPD)

Latest News

  1. Biotech Stock On The Radar: Is Vanda A Buy Ahead Of Its PDUFA Date?
  2. The Week Ahead In Biotech: Vanda Awaits FDA Decision, BioVie Plans IPO
  3. Edited Transcript of VNDA earnings conference call or presentation 31-Jul-19 8:30pm GMT
  4. Why Vanda (VNDA) Might be Well Poised for a Surge
  5. Vanda Pharmaceuticals Returns to Profitability in Q2
  6. Should You Be Worried About Insider Transactions At Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)?
  7. This D.C. biotech has hit some bumps this year. It’s also breaking revenue records.
  8. Here's Why Vanda Pharmaceuticals Stock Soared on Thursday
  9. This Medtech's CEO Promised To 'Correct The Course' — That Didn't Happen
  10. Vanda Pharmaceuticals (VNDA) Q2 2019 Earnings Call Transcript
  11. Vanda Pharmaceuticals (VNDA) Surpasses Q2 Earnings and Revenue Estimates
  12. Vanda Pharmaceuticals Reports Second Quarter 2019 Financial Results
  13. Shareholder Alert: Robbins Arroyo LLP: Vanda Pharmaceuticals Inc. (VNDA) Sued for Misleading Investors
  14. Analysts Estimate Vanda Pharmaceuticals (VNDA) to Report a Decline in Earnings: What to Look Out for
  15. The Daily Biotech Pulse: Acadia Schizophrenia Drug Fails, Viveve Plummets, Eisai Gets Breakthrough Therapy Designation
  16. Vanda Pharmaceuticals to Announce Second Quarter 2019 Financial Results on July 31, 2019
  17. FDA points to deficiencies in Vanda's latest drug application
  18. Vanda Pharmaceuticals FDA Update for HETLIOZ® in the Treatment of Jet Lag Disorder
  19. How Do You Test a New Seasickness Drug? Take Pill, Set Sail
  20. Nausea no more? D.C. biotech gets motion sickness drug to next stage.